Adjuvant chemotherapy use among older patients with stage III colon cancer

JAMA

Volumn 303, Issue 23, 2010, Pages 2353-

  Moore, Maggie ^a   Gibbs, Peter ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN;

CANCER ADJUVANT THERAPY; COLON CANCER; COMORBIDITY; GOOD CLINICAL PRACTICE; GROUPS BY AGE; HUMAN; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; AGED; COLON TUMOR; DECISION MAKING; NOTE; PRACTICE GUIDELINE;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DECISION MAKING; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 77953640749     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.775     Document Type: Letter

References (5)

1. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010;303(11):1037-1045.
2. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-3116.
3. Ananda S, Field KM, Kosmider S, et al. Patient age and co-morbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. J Clin Oncol. 2008;26(27):4516-4517.
4. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and co-morbidity? J Clin Oncol. 2008;26(15):2532-2537.
5. Tan E, Tilney H, Thompson M, Smith J, Tekkis PP; Association of Coloproctology of Great Britain and Ireland. The United Kingdom National Bowel Cancer Project: epidemiology and surgical risk in the elderly. Eur J Cancer. 2007;43(15):2285-2294.